Determination of anthraquinone prodrug and its hydrolytically active compounds using RP-HPLC

Journal of Southeast University (English Edition)

Volumn 25, Issue 1, 2009, Pages 128-131

  Duan, Yanbing ^a   Yu, Jia ^a   Liu, Haifeng ^a   Ji, Min ^a  

^a SOUTHEAST UNIVERSITY   (China)

Author keywords

Active components; Anthraquinone prodrug; High performance liquid chromatography (HPLC); Quantitative analysis

Indexed keywords

ACTIVE COMPONENTS; ACTIVE COMPOUNDS; ANALYTES; ANTHRAQUINONE PRODRUG; ANTI-INFLAMMATORY; CHROMATOGRAPHIC SEPARATIONS; CONCENTRATION RANGES; HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY (HPLC); IN-VITRO; LINEAR BEHAVIORS; MOBILE PHASE; MOBILE PHASE FLOW RATES; QUANTITATIVE ANALYSIS; REVERSE-PHASE HIGH-PERFORMANCE LIQUID CHROMATOGRAPHIES; RP-HPLC; SIMULTANEOUS DETERMINATIONS; VALIDATED METHODS;

CHROMATOGRAPHIC ANALYSIS; CHROMATOGRAPHY; HIGH PRESSURE LIQUID CHROMATOGRAPHY; KETONES; LIQUIDS; METHANOL; PHOSPHORIC ACID; PINCH EFFECT;

HIGH PERFORMANCE LIQUID CHROMATOGRAPHY;

EID: 65349179016     PISSN: 10037985     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Wang D, Sima M, Mosley R, et al. Pharmacokinetic and biodistribution studies of a bone-targeting drug delivery system based on N-(2-hydroxypropyl) methacrylamide copolymers [J]. Molecular Pharmaceutics, 2006, 3 (6): 717-725.
2. Dharap S, Wang Y, Chandna P, et al. Tumor-spectific targeting of an anticancer drug delivery system by LHRH peptide [J]. Proceedings of National Academy of Sciences of the United States of America, 2005, 102 (36): 12962-12967.
3. Kumpulainen H, Jarvinen T, Mannila A, et al. Synthesis, in vitro and in vivo characterization of novel ethyl dioxy phosphate prodrug of propofol [J]. European Journal of Pharmaceutical Sciences, 2008 34 (2/3): 110-117.
4. Rotem E, Sharon E, Bernard A, et al. Chemotherapeutic bone-targeted biophosphonate prodrugs with hydrolytic mode of activation [J]. Bioorganic & Medicinal Chemistry Letters, 2008, 18 (2): 816-820.
5. Itokawa H, Morris-Natschke Susan L, Akiyama T, et al. Plant-derived natural product research aimed at new drug discovery [J]. Journal of Natural Medicines, 2008, 62 (3): 263-280.
6. Tamuraa T, Shiraia T, Kosakaa N, et al. Pharmacological studies of diacerein in animal models of inflammation, arthritis and bone resorption [J]. European Journal of Pharmacology, 2002, 448 (1): 81-87.
7. Gonnot V, Tisserand S, Nicolas M, et al. Total synthesis of rhein and diacerhein via a directed ortho metalation of an aromatic substrate [J]. Tetrahedron Letters, 2007, 48 (40): 7117-7119.
8. Debord P, Louchahi K, Tod M, et al. Influence of renal function on the pharmacokinetics of diacerein after a single oral dose [J]. European Journal of Drug Metabolism and Pharmacokinetics, 1994, 19 (1): 13-19.
9. Tamura T, Kosaka N, Ishiwa J, et al. Rhein, an active metabolite of diacerein, down-regulates the production of pro-matrix metalloproteinases-1,-3,-9 and -13 and up-regulates the production of tissue inhibitor of metalloproteinase-1 in cultured rabbit articular chondrocytes [J]. Osteoarthritis and Cartilage, 2001, 9 (3): 257-263.
10. Perrin D. Binding of tetracyclines to bone [J]. Nature, 1965, 208 (11): 787-788.
11. Wang Y, Chen H, Wan Z, et al. Synthesis of a new series of bone affinity compounds [J]. Chinese Chemical Letters, 2007, 17 (3): 310-312.